-
- 平澤 由平
- 信楽園病院内科
-
- 鈴木 正司
- 信楽園病院内科
-
- 伊丹 儀友
- 日鋼記念病院腎センター
-
- 大平 整爾
- 日鋼記念病院腎センター 札幌北クリニック
-
- 水野 紹夫
- 三愛病院
-
- 米良 健太郎
- 日東病院
-
- 芳賀 良春
- 日東病院
-
- 河合 弘進
- 済生会前橋病院
-
- 真下 啓一
- 済生会前橋病院
-
- 小原 功裕
- さくら記念病院
-
- 黒澤 範夫
- さくら記念病院
-
- 中本 安
- 東仁会吉祥寺あさひ病院
-
- 沼澤 和夫
- 東仁会吉祥寺あさひ病院
-
- 古橋 三義
- 新風会丸山病院
-
- 丸山 行孝
- 新風会丸山病院
-
- 三木 隆治
- 豊橋メイツクリニック
-
- 小池 茂文
- 豊橋メイツクリニック
-
- 勢納 八郎
- 偕行会名古屋共立病院, 偕行会セントラルクリニック
-
- 川原 弘久
- 偕行会名古屋共立病院, 偕行会セントラルクリニック
-
- 小林 裕之
- 桃仁会病院
-
- 小野 利彦
- 桃仁会病院
-
- 奥野 仙二
- 仁真会白鷺病院内科
-
- 金 昌雄
- 仁真会白鷺病院内科
-
- 宮崎 良一
- 藤田記念病院
-
- 雑賀 保至
- 良秀会藤井病院藤井診療所
-
- 本宮 善恢
- 翠悠会診療所
-
- 谷合 一陽
- 岡山中央病院
-
- 碓井 公治
- 一陽会クリニック
-
- 重本 憲一郎
- 一陽会原田病院
-
- 水口 隆
- 鴨島川島クリニック
-
- 川島 周
- 川島病院
-
- 湯浅 健司
- 尚腎会高知高須病院
-
- 大田 和道
- 尚腎会高知高須病院
-
- 佐藤 隆
- 古賀クリニック
-
- 福成 健一
- 古賀病院21
-
- 木村 祐三
- 木村クリニック
-
- 高橋 尚
- 高橋内科クリニック
-
- 由宇 宏貴
- 高橋内科クリニック
書誌事項
- タイトル別名
-
- Maintenance hamatocrit levels and mortality in hemodialysis patients with renal anemia receiving recombinant human erythropoietin(rHuEPO) treatment(rHuEPO survey).
この論文をさがす
抄録
A total of 2, 654 maintenance hemodialysis patients with at feast 6 months history of dialysis, who had been continuously treated with recombinant human erythropoietin (rHuEPO) over 6 months, were included in this study. The association between maintenance hematocrit levels and patient mortality was retrospectively studied. A Cox regression analysis was performed to evaluate mortality risks. Patients with hematocrit values of 30% to <33% exhibited significantly lower 1-year mortality risk (0.447 [95% confidence intervals (CI): 0.290-0.689] p=0.0003), when compared to patients with the reference hematocrit range, 27% to <30% (reference group) [Relative Risk (RR): 1.000]. However, there was no significant difference in the 1-year mortality risk between patients with hematocrit values of 33% to <36% (0.605 [95% CI: 0.320-1.146] p=0.1231) and the reference group. On the other hand, compared to the reference group, patients with hematocrit values of <27% exhibited significantly higher risk of death during the 1-year follow-up period (1.657 [95% CI: 1.161-2.367] p=0.0054). A similar pattern was observed for 3-year mortality risks. Compared to the reference group, patients with hematocrit values of 30% to <33% exhibited significantly lower 3-year mortality risk (0.677 [95% CI: 0.537-0.855] p=0.0010). However, there was no significant difference in 3-year mortality risk between patients with hematocrit values of 33% to <36% (1.111 [95% CI: 0.816-1.514] p=0.5036) and the reference group. Compared to the reference group, patients with hematocrit values of <27% exhibited significantly higher risk of death during the 3-year follow-up period (1.604 [95% CI: 1.275-2.019] p<0.0001).<br>These observations demonstrate that patients with hematocrit values of 30% to less than 33% have significantly lower risk for 1-year and 3-year mortality, when compared to patients with hematocrit values of 27% to <30%. Based on mortality, our findings suggest that the maintenance hematocrit level of 30% to less than 33% is favorable for hemodialysis patients with rHuEPO treatment. Though there were few patients with hematocrit values of 33% or higher, these patients exhibited lower risk of death during the 1-year follow-up period. Further study is needed to clarify the benefit of these high hematocrit levels.
収録刊行物
-
- 日本透析医学会雑誌
-
日本透析医学会雑誌 36 (7), 1265-1272, 2003
一般社団法人 日本透析医学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679651306240
-
- NII論文ID
- 10011427254
-
- NII書誌ID
- AN10432053
-
- ISSN
- 1883082X
- 13403451
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可